Global Drugs of UDCA Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs of UDCA Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
Drugs of UDCA report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs of UDCA market is projected to reach US$ 3389.8 million in 2029, increasing from US$ 1645 million in 2022, with the CAGR of 10.7% during the period of 2024 to 2029. Demand from Gallstone and Hepatopathy are the major drivers for the industry.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs of UDCA market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Gallstone
Hepatopathy
Biliary Disease
Other
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs of UDCA market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs of UDCA, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs of UDCA industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs of UDCA in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs of UDCA introduction, etc. Drugs of UDCA Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs of UDCA market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Drugs of UDCA report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs of UDCA market is projected to reach US$ 3389.8 million in 2029, increasing from US$ 1645 million in 2022, with the CAGR of 10.7% during the period of 2024 to 2029. Demand from Gallstone and Hepatopathy are the major drivers for the industry.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs of UDCA market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Segment by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs of UDCA market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs of UDCA, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs of UDCA industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs of UDCA in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs of UDCA introduction, etc. Drugs of UDCA Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs of UDCA market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices